AbbVie is sued for using Humira patent deals to block competition - STAT

AbbVie is sued for using Humira patent deals to block competition - STAT

STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.

By ED SILVERMAN

DAVID J. PHILLIP/AP

The patent deals restrict the other drug makers from selling biosimilar versions of Humira in the U.S. until 2023, but sales are permitted in Europe

READ MORE